| Product Name | (1R,2R)-Bortezomib-d5 |
| Product Code | DA-B169-57 |
| Chemical name | (1R,2R)-Bortezomib-d5 |
| Synonyms | B-[(1R)-3-Methyl-1-[[(2R)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic-d5 Acid; [(1R)-3-Methyl-1-[[(2R)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic-d5 Acid; |
| Impurity | NA |
| CAS Number | NA |
| Alternate CAS # | NA |
| Molecular form | C19H20D5BN4O4 |
| Appearance | NA |
| Melting Point | NA |
| Mol. Weight | 389.27 |
| Storage | 2-8°C Refrigerator |
| Solubility | NA |
| Stability | NA |
| Category | chiral standards,boron derivatives,enzyme inhibitors,pharmaceutical standards,intermediates,Fine Chemicals,stable isotopes |
| Boiling Point | NA |
| Applications | Labelled (1R,2R)-Bortezomib is a diastereomer of Bortezomib, the first proteasome inhibitor to be approved by the US FDA for multiple myeloma, a blood cancer. A reversible inhibitor of the 26S proteasome-a barrel-shaped multiprotein particle found in the nucleus and cytosol of all eukaryotic cells. Targets the ubiquitin-proteasome pathway |
| Dangerous Goods Info | NA |
| References | NA |
| Extra Notes | NA |
| Documents (MSDS) | No Data Available |
| Keywords | NA |
